XGBoost-based machine learning test improves the accuracy of hemorrhage prediction among geriatric patients with long-term administration of rivaroxaban

[1] Ouellet GM(2021)Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of Life JAMA Intern Med 181 1121-1123

[2] Fried TR(2019)Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation Ageing Res Rev 49 115-124

[3] Gilstrap LG(2021)Stroke prevention strategies in high-risk patients with atrial fibrillation Nat Rev Cardiol 18 276-290

[4] O'Leary JR(2019)Anticoagulation after surgical or transcatheter bioprosthetic aortic valve replacement J Am Coll Cardiol 74 1190-1200

[5] Austin AM(2017)Rivaroxaban- metabolism, pharmacologic properties and drug interactions Curr Drug Metab 18 636-642

[6] Skinner JS(2021)The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis Am J Cardiovasc Drugs 21 51-61

[7] Cohen AB(2021)Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis Clin Cardiol 44 1208-1215

[8] Kato ET(2017)Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis Stroke 48 970-976

[9] Goto S(2019)Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis J Am Heart Assoc 8 e012540-919

[10] Giugliano RP(2021)Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study Ann Intern Med 174 910-S11

[1] Ouellet GM(2021)Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of Life JAMA Intern Med 181 1121-1123

[2] Fried TR(2019)Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation Ageing Res Rev 49 115-124

[3] Gilstrap LG(2021)Stroke prevention strategies in high-risk patients with atrial fibrillation Nat Rev Cardiol 18 276-290

[4] O'Leary JR(2019)Anticoagulation after surgical or transcatheter bioprosthetic aortic valve replacement J Am Coll Cardiol 74 1190-1200

[5] Austin AM(2017)Rivaroxaban- metabolism, pharmacologic properties and drug interactions Curr Drug Metab 18 636-642

[6] Skinner JS(2021)The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis Am J Cardiovasc Drugs 21 51-61

[7] Cohen AB(2021)Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis Clin Cardiol 44 1208-1215

[8] Kato ET(2017)Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis Stroke 48 970-976

[9] Goto S(2019)Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis J Am Heart Assoc 8 e012540-919

[10] Giugliano RP(2021)Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study Ann Intern Med 174 910-S11